VRCI Verici Dx Plc

TIDMVRCI

RNS Number : 7012B

Verici Dx PLC

06 June 2023

Verici Dx plc

("Verici Dx" or the "Company")

Posting of Annual Report & Accounts

and

Notice of Annual General Meeting

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, confirms that the Annual Report and Accounts for the year ended 31 December 2022 ("2022 Annual Report") and the Notice of the 2023 Annual General Meeting ("AGM") have now been published on the Company's website: vericidx.com/investors/ .

The 2022 Annual Report, the Notice of AGM and details for voting by proxy will be posted to shareholders who have not consented to receive electronic communications today, on 6 June 2023.

The AGM is to be held at 2:00pm on Thursday 29 June 2023 at the Company's registered offices, at Avon House, 19 Stanwell Road, Penarth, Cardiff, CF64 2EZ and will consider the Resolutions set out in the Notice of AGM.

The Company is providing a facility for shareholders to listen in to the AGM either online or telephonically (in a non-voting capacity) and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Directors would request that shareholders register for the meeting and submit questions in advance, before 3:00pm on 27 June 2023. To register for dial-in details and to submit any questions please contact Walbrook PR via email at vericidx@walbrookpr.com or call +44 (0)20 7933 8780.

Proxy voting

Shareholders will not receive a hard copy form of proxy for the AGM in the post. Instead, Shareholders will be able to vote electronically using the link www.signalshares.com . Proxy votes must be received no later than 2:00pm on 27 June 2023.

Shareholders may request a hard copy form of proxy directly from the Registrars, Link Group, on Tel: 0371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales. Alternatively, shareholders can vote by downloading the new app, LinkVote+, on Apple App Store or Google Play and following the instructions.

Enquiries:

 
Verici Dx                                                                www.v ericidx .com 
Sara Barrington, CEO                                                        Via Walbrook PR 
Julian Baines, Chairman 
 
Singer Capital Markets (Nominated Adviser                             Tel: +44 20 7496 3000 
 & Broker) 
Aubrey Powell / Sam Butcher 
 
Walbrook PR Limited                        Tel: +44 20 7933 8780 or vericidx@walbrookpr.com 
Paul McManus / Stephanie Cuthbert /                        Mob: +44 7980 541 893 / +44 7796 
 Sam Allen                                                                        794 663 / 
                                                                              07502 558 258 
 

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

Verici Dx's two lead products are Tutivia(TM), a post-transplant test focused upon acute cellular rejection, including sub-clinical rejection and Clarava(TM), a pre-transplant prognosis test for the risk of early acute rejection. These products seek to measure how a patient is likely to respond, and is responding, to a kidney transplant. These products are underpinned by extensive patented and published scientific research from the leading Mount Sinai Medical Center, for which the Company holds an exclusive worldwide licence.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAEELFBXQLFBBQ

(END) Dow Jones Newswires

June 06, 2023 02:00 ET (06:00 GMT)

Verici Dx (LSE:VRCI)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Verici Dx (LSE:VRCI)
Historical Stock Chart
Von Dez 2023 bis Dez 2024